Intervacc AB (publ) (STO:IVACC)
Sweden · Delayed Price · Currency is SEK 0.6210
+0.0010 (0.16%)
Feb 26, 2026, 5:29 PM CET
Intervacc AB Revenue
In the year 2025, Intervacc AB had annual revenue of 20.09M SEK with 70.42% growth. Intervacc AB had revenue of 3.12M in the quarter ending December 31, 2025, a decrease of -24.33%.
Revenue
20.09M
Revenue Growth
+70.42%
P/S Ratio
10.54
Revenue / Employee
1.34M
Employees
15
Market Cap
211.64M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 20.09M | 8.30M | 70.42% |
| Dec 31, 2024 | 11.79M | 3.76M | 46.84% |
| Dec 31, 2023 | 8.03M | -4.33M | -35.01% |
| Dec 31, 2022 | 12.35M | 3.43M | 38.43% |
| Dec 31, 2021 | 8.92M | 1.91M | 27.20% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Magle Chemoswed Holding AB | 300.49M |
| Sprint Bioscience AB | 167.17M |
| Bio-Works Technologies AB | 63.11M |
| NextCell Pharma AB | 11.06M |
| Elicera Therapeutics AB | 10.86M |
| Xintela AB | 2.96M |
| Lipum AB | 398.00K |
| Mendus AB | -1.44M |
Intervacc AB News
- 13 days ago - Earnings To Watch: Intervacc AB (OSTO:IVACC) Reports Q4 2025 Result - GuruFocus
- 3 months ago - What To Expect From Intervacc AB (OSTO:IVACC) Q3 2025 Earnings - GuruFocus